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Abstract
Background: Human interacting protein X1 (PinX1) has been identified as a critical telomerase inhibitor and
proposed to be a putative tumor suppressor gene. Loss of PinX1 has been found in a large variety of malignancies,
however, its function in inhibiting telomerase activity of tumor cells is not well documented. Here we show that
PinX1 is essential for down-regulation telomerase activity of nasopharyngeal carcinoma.
Methods: Expression vectors of human PinX1 (pEGFP-C3-PinX1) and its small interfering RNA (PinX1-FAM-siRNA)
were constructed and transfected into NPC. Their effects on mRNA of telomerase catalytic subunit (hTERT),
telomerase activity, cell proliferation, cell migration, wound healing, cell cycles and apoptosis were examined using
semi-quantitative RT-PCR, stretch PCR, MTT assay, Transwell, scratch assay and flow cytometry, respectively.
Results: Transfection of pEGFP-C3-PinX1 and PinX1-FAM-siRNA increased and reduced PinX1 mRNA by 1.6-fold and
70%, respectively. Over-expression of PinX1 decreased hTERT mRNA by 21%, reduced telomerase activity, inhibited
cell growth, migration and wound healing ability, arrested cells in G0/G1 phase, and increased apoptotic index. In
contrast, down-regulation of PinX1 did not alter the above characteristics.
Conclusions: PinX1 may play important roles in NPC proliferation, migration and apoptosis and has application
potential in tumor-targeted gene therapy.
Keywords: PinX1, Telomerase inhibitor, Proliferation, Migration, Apoptosis, Cell cycle, Human nasopharyngeal
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Background
Nasopharyngeal carcinoma (NPC) is one of the most
incident and dangerous malignant tumors in southern
provinces of China. Genetic factors and environmental
factors including Epstein-Barr virus are the two major
risk factors for NPC. Radiotherapy along with other aux-
iliary methods such as chemotherapy is used to treat
NPC. Although equipments and technologies in radio-
therapy and chemotherapy have been greatly advanced
in recent years, the 5-year survival rate of patients with
NPC remains about 70%. In addition, systemic and local
side effects caused by chemotherapy greatly humbled
the patient physically and psychologically. Therefore, it
is of importance to study the etiology of NPC and
explore new, safe and effective modalities for NPC
therapy.
Telomerase is well known for its role in the develop-
ment of malignant tumors. Studies from our group and
others [1,2] have found enhanced mRNA level of telo-
merase catalytic subunit (TERT) and telomerase expres-
sion in 88% of NPC specimens and NPC cell line HNE1.
Antisense nucleic acid targeted to telomerase RNA
and hTERT can inhibit telomerase activity and induce
apoptosis of tumor cells [3,4].
Suicide genes TK and CD are powerful in cancer gene
therapy. However, their application has been limited due
to lack of targeting. Using targeted promoter such as
hTERT promoter to regulate suicide gene expression
has been a direction in tumor gene therapy. In recent
years, we have constructed tumor specific TK expression
and enhanced expression vectors using hTERT
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could specifically kill NPC and its stem cells in vitro and
inhibit NPC exograft in null mice in vivo without dama-
ging normal cells and mouse liver and kidney [5-7],
indicating that inhibition of telomerase activity is a key
step to in NPC treatment.
Study on telomerase inhibitors has become an impor-
tant area in targeted tumor gene therapy. Pin2/TRF1
interacting protein X1 (PinX1) was recently found as a
tumor suppressor and telomerase inhibitor in vivo.I ti s
expressed in normal human tissues, but not or less
expressed in tumor tissues. Studies have found that
PinX1 can inhibit telomerase activity in gastric and liver
tumor cells and induce their apoptosis [8-11]. The
expression of PinX1 has been positively correlated with
telomerase activity in leukemia [12,13]. However, some
studies on prostate cancer, gastrointestinal cancer and
medulloblastoma indicate that gene polymorphism
rather than PinX1 expression is the key factor in inhibit-
ing telomerase [14-16] and PinX1 as a microtubule
binding protein plays an important role in stabilizing
chromosome [17]. In short, the mechanisms by which
PinX1 regulates telomerase/telomere in tumor cells are
complex and may vary in different tumors.
The effect of PinX1 on NPC apoptosis and the
mechanisms by which PinX1 affects telomerase activity
have not been reported. Therefore, in this study, we
constructed PinX1 expression vector and utilized its
small interfering RNA to study its possible role in NPC.
Methods
Materials
Austria newborn calf serum, RT-PCR kit and DNA mar-
ker were from Takara Biotechnology Co., Ltd. Tetrazo-
lium blue (MTT) was from Sigma. Lipofectamine
2000™ and RNA extraction reagent Trizol were from
Invitrogen (USA). Transwell cell culture plates were
from Corning (USA). Plasmid extraction kit was from
Tiangen Biotech (Beijing) Co. Ltd. Telomerase activity
detection kit was from Toyobo Corporation.
Cell lines
Human nasopharyngeal carcinoma 5-8 F cells (NPC 5-8
F) and human vascular endothelial cells (VEC) were
maintained in RPMI 1640 and DMEM, respectively, sup-
plemented with 10% calf serum, 100 U/mL penicillin
and 100 U/mL streptomycin at 37°C in a 5% CO2 incu-
bator as previously reported. After passaged using con-
ventional method, cells were used for experiment at
logarithmic phase.
Plasmid construction
Synthesized PinX1 DNA was inserted into pEGFP-C3
vector at XhoI and EcoRI sites. Recombinant plasmid
was transformed into E. coli DH5a and screened by
kanamycin and neomycin resistance. Possitive pEGFP-
C3-PinX1 was further identified by XhoI and EcoRI
digestion and confimed by DNA sequencing.
PinX1 siRNA
PinX1 siRNAs were designed using online software from
Invitrogen company (http://maidesigner.Invitrogen.com/
maiexpress/). After blast and analysis for homology in
human genome, three siRNAs PinX1-963, PinX1-695
and PinX1-242 were selected and used to silence PinX1.
Preliminary experiments indicated that PinX1-695 with
sense sequence of 5’-GUAAAGAUGUGGAAA-
GUUATT-3’ and anti-sense sequence of 5’-TTCAUUU-
CUACACCUUUCAAU-3’ could effectively
downregulate PinX1. Threrefore, it was synthesized as
FAM-labeled siRNA and used in all experiments.
Experimental design and cell transfection
Cells at logarithmic phase were innoculated into 6-well
plated cultured in media without antibiotics for 24 h to
reach 80-90% confluency. Cells were then transfected
with pEGFP-C3-PinX1, and PinX1-FAM-siRNA using
lipofectimaine 2000™ according to the protocol pro-
vided by the manufacturer. Untransfected cells and cells
treated with lipofectimine 2000™ alone and cells trans-
fected with pEGFP-C3 were used as controls. Cells were
observed 24-48 h after transfection under fluorescence
microscope to examine transfection efficiency.
RNA isolation and measurement of PinX1 and hTERT
mRNA levels by RT-PCR
Total RNA was extracted with Trizol 48 h after trans-
fection following the manufacturer’s instruction. Four
μL mRNA of each sample was reverse transcribed into
cDNA by AMV reverse transcriptase and used as tem-
plate in RT-PCR. PCR condition used for PinX1 and
internal reference GAPDH was 94°C for 2 min followed
by 25 cycles of 94°C for 1 min, 55°C for 1 min and 72°C
f o r2m i n ,a n d7 2 ° Cf o r5m i n .P C Rc o n d i t i o nu s e df o r
hTERT and its internal reference GAPDH was 94°C for
4 min followed by 30 cycles of 94°C for 30 s, 49°C for
30 s and 72°C for 45 s and 72°C for 5 min. The specific
primers used in these reactions were followings: PinX1
forward 5’ TTTTCTCGAGATGTCTATGCTGGCT-
GAACG 3’ and reverse 5’ TTTTGAATTCTCATTTG-
GAATCTTTCTTC 3’;h T E R Tf o r w a r d5 ’
CCGAGTGACCGTGGTTTCTGTG 3’ and reverse
5’GGAAGCGGCGTTCGTTGTG 3’ and GAPDH for-
ward 5’ GGAAGATGGTGATGGGATT 3’ and reverse
5’ GGATTTGGTCGTATTGGG 3’. The expected PCR
products were 987 bp, 670 bp and 205 bp for PinX1,
hTERT and GAPDH, respectively. The amplicons were
analyzed by electrophoresis, imaged using UVI gel
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ware. Expression levels of PinX1 and hTERT were nor-
malized to internal reference GAPDH.
Measurement of cell proliferation by MTT
NPC 5-8 F cells at logarithmic phase were inoculated
into 96-well plate with 1 × 10
5 cells in each well. Cell
viability at 0 h, 24 h, 48 h and 72 h was examined using
MTT method. OD490nm values at each time point were
detected in six duplicate wells and their averages were
used to plot growth curve and calculate the growth inhi-
bition rate of each treatment using the following for-
mula:
Growth inhibition rate Ir = OD490nm of the control group − OD490nm of the treatment group
/OD490nm of the control group × 100%
Detection of telomerase activity by stretch PCR
NPC 5-8 F cells at logarithmic phase were inoculated
into 6-well plate with 1 × 10
6/well. 24 h later, cells were
transfected as described above. 48 h after transfection,
telomerase activity was measured using stretch PCR
assay based on the protocol provided by the manufac-
turer. Meanwhile, telomerase activity in control ECV-
304 cells was similarly examined.
Effect of PinX1 on cell migration
Cell migration was examined using transwell. In detail,
NPC 5-8 F cells at logarithmic phase were starved over-
night in serum free RPMI 1640 media. Cells were deat-
tached with 0.25% trypsin. After wash with PBS, they
were resuspended in RPMI 1640 containing 1 mmol/L
CaCl2,1m m o l / LM g C l 2,0 . 2m m o l / LM n C l 2 and 5 g/L
BSA, and adjusted to 1 × 10
5/mL. 200 μL cell suspen-
sion was added into the upper chamber of the transwell
and 500 μL RPMI 1640 containing 10% newborn calf
serum (as a chemokine) was added into the lower cham-
ber of the transwell. The transwell was then cultured at
37°C in a incubator supplemented with 5% CO2.2 4h
later, cells on the upper surface of polycarbonate mem-
brane of the transwell were removed with a cotton swab
and the cells that migrated onto the lower surface of the
membrane were fixed with 4% paraformaldehyde for 15
min, washed three times with PBS for 5 min each and
stained with crystallization violet for 3 min. After
further wash with PBS, the membrane was air dried and
cell number on the membrane was counted under
microscope at 400 magnification. The number of
migrated cells was expressed as the average of five ran-
domly selected fields.
Scratch assay
Transfected NPC 5-8 F cells at logarithmic phase were
inoculated in 6-well plate pre-coated with collagen IV.
When monolayer was formed, cells were scratched with
a 100 μL tip and cultured in media containing 10% FBS.
Zero, 12, 24, and 36 h after scratching, cells in each well
were photographed under microscope. The distances
between the two edges of the scratched cells in four
fields were measured and the average distance was used
to calculate the healing rate using the following formula:
Healing rate = the distance befor healing − the distance after healing
/the distance before healing) × 100% .
Measurement of cell cycle and apoptosis by flow
cytometry
48 h after transfection, NPC 5-8 F cells were collected,
washed with PBS, resuspended in PBS at 1 × 10
6/mL,
and stained with Annexin V and propidium iodide solu-
tion (PI) for 15 min at dark. Apoptotic cells were then
analyzed by flow cytometry and apoptotic index (AI)
was calculated using AI = apoptotic cells/total cells ×
100%. Cell cycle was determined after fixing with pre-
cooled 75% ethanol at 4°C and wash with PBS.
Statistical analysis
Data were expressed as mean ± standard variation ¯ X ± s
and analyzed using SPSS13.0 statistical software package.
Differences between samples in RT-PCR, telomerase
activity, migration assay, scratch assay, cell cycle and
apoptosis assay were tested using single factor analysis
of variance and LSD method for multiple comparisons.
Differences in between samples in proliferation assay or
scratch assay were tested using factorial design analysis
of variance and Dunnett’s T3 method for multiple com-
parisons. A p value less than 0.05 was considered as sig-
nificant difference. Before comparison, data
homogeneity of variance was first examined using F test.
In the case of heterogeneity of variance, the approximate
variance F test/Welch method was used.
Results
We first confirmed the successful construction of PinX1
expression vector pEGFP-C3-PinX1 by digestion with
Figure 1 The sequencing map of PinX1 gene.
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sis, As shown in Figure 1.
We then examined the transfection efficient under
fluorescence microscope. As shown in Figure 2, above
50% of cells were transiently transfected.
We next detected PinX1 mRNA level in tranfected
c e l l sb yR T - P C R .A ss h o w ni nF i g u r e3 ,a ne x p e c t e d
fragment of 987 bp was amplified in samples isolated
from non-transfected NPC 5-8 F cells, lipofectamine
treated cells, and cells transfected with pEGFP-C3-
PinX1 and pEGFP-C3, respectively, but not in NPC 5-8
F cells transfected with PinX1-FAM-siRNA. Its intensity
was the strongest in cells transfected with pEGFP-C3-
PinX1. As shown in Table 1, PinX1 mRNA level in cells
transfected with pEGFP-C3-PinX1 is 1.6-fold of that in
untreated cells (p < 0.05). By contrast, PinX1 mRNA
level in cells transfected with PinX1-FAM-siRNA
reduced by 70% compared with that in untreated cells
(p < 0.05). In addition, PinX1 mRNA level in cells trea-
ted with lipofectimine alone or transfected with pEGFP-
C3 was not significantly changed (p > 0.05).
Having confirmed that transfection of pEGFP-C3-
PinX1 and PinX1-FAM-siRNA could significantly
  
Figure 2 Images of nasopharyngeal carcinoma 5-8 F cells transfected with plasmid pEGFP-C3-PinX1 under bright field (a) and
fluorescent field (b) and transfected with PinX1-FAM-siRNA under bright field (c) and fluorescent field (d).
Figure 3 Electrophoresis analysis of RT-PCR amplicons from
PinX1 mRNA isolated from nasopharyngeal carcinoma 5-8 F
cells transfected with (a) pEGFP-C3-PinX1, (b) pEGFP-C3, (c)
PinX1-FAM-siRNA, respectively, and treated with (d)
lipofectamine alone and (e) control, respectively, showing
relative PinX1 mRNA level.
Table 1 PinX1 mRNA levels (¯ X ± s)
Sample mRNA F P
pEGFP-C3-PinX1 1.601 ± 0.166* 24.756 0.00
pEGFP-C3 1.223 ± 0.148
Lipofectamine alone 1.042 ± 0.166
Untreated 1.000 ± 0.000
PinX1-FAM-siRNA 0.304 ± 0.055**
* vs untreated, P < 0.001; ** vs untreated, P < 0.05. PinX1 mRNA level was
normalized to GAPDH.
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then explored their effects on NPC 5-8 F cell prolifera-
tion using MTT assay. As shown in Table 2, factorial
design analysis of variance found that the mean value
of OD490nm in cells transfected with pEGFP-C3-PinX1
was 2.15, which was significantly decreased compared
with that of 2.52 and 2.50 in untreated NPC 5-8 F
cells and cells transfected with PinX1-FAM-siRNA,
respectively (F = 31.504, p = 0.000). In addition, there
was no significant difference in the mean value of
OD490nm in untreated cells, lipofectimine treated cells,
cells transfected with pEGFP-C3 and cells transfected
with PinX1-FAM-siRNA. Figure 4 shows the cell
g r o w t hc u r v eb yp l o t t i n gt h eO D 490nm value vs time (0
h, 24 h, 48 h and 72 h). Cell growth rate calculated
based on the curve indicated that overexpression of
PinX1 significantly inhibited the growth of NPC 5-8 F
cells, whereas downregulation of PinX1 by siRNA
transfection did not affect the growth of NPC 5-8 F
cells.
We further explored the effect of PinX1 on NPC 5-8 F
cell migration. As shown in Table 3 and Figure 5, over-
expression of PinX1 by transfecting pEGFP-C3-PinX1
significantly decreased NPC 5-8 F migration compared
with untreated cells (F = 17.162, p = 0.000). By contrast,
attenuated Pin X1 expression by transfection of PinX1-
FAM-siRNA did not affect NPC 5-8 F cell migration (p
> 0.05). In addition, transfection of pEGFP-C3 and treat-
ment with lipofectimine alone did not alter the ability of
NPC 5-8 F migration (p > 0.05).
We next studied the effects of PinX1 on wound heal-
ing ability. As shown in Figure 6, factorial design analy-
sis of variance showed that overexpression of PinX1 by
transfection of pEGFP-C3-PinX1 significantly attenuated
the mean healing rate of untreated 5-8 F cells from
37.80% to 23.74%, and the healing rates at 12 h, 24 h
and 36 h (p < 0.001). By contrast, the healing rate of
NPC 5-8 F cells was not affected by treatment of lipo-
fectamine alone and transfection of pEGFP-C3 and
PinX1-FAM-siRNA (p > 0.05).
We then examined the effect of PinX1 on hTERT
mRNA level and telomerase activity. As shown in Tables
4 and 5 and Figures 7 and 8, overexpression of Pin X1
by transfection of pEGFP-C3-PinX1 significantly
Table 2 OD490nm value of NPC 5-8 F cells (¯ X ± s)
Sample Time Total Welch/F Value P Value
0 h 24 h 48 h 72 h
pEGFP-C3-PinX1 1.86 ± 0.07 2.02 ± 0.11 2.23 ± 0.08 2.58 ± 0.03 2.15 ± 0.27 74.246 0.000
pEGFP-C3 1.85 ± 0.04 2.27 ± 0.17 2.66 ± 0.15 3.07 ± 0.23 2.44 ± 0.47 57.327 0.000
Lipofectamine alone 1.87 ± 0.05 2.30 ± 0.10 2.72 ± 0.13 3.12 ± 0.08 2.48 ± 0.47 156.436 0.000
Untreated 1.88 ± 0.02 2.39 ± 0.23 2.78 ± 0.19 3.15 ± 0.12 2.52 ± 0.50 189.669Δ 0.000
PinX1-FAM-siRNA 1.87 ± 0.01 2.35 ± 0.05 2.75 ± 0.04 3.14 ± 0.12 2.50 ± 0.47 720.110Δ 0.000
Total 1.87 ± 0.04 2.27 ± 0.19 2.63 ± 0.24 3.01 ± 0.25 2.42 ± 0.46 437.621* 0.000
Welch/F value 0.309 5.696 35.155Δ 5.600 35.870* F = 4.592#
P value 0.869 0.002 0.000 0.000 0.000 P = 0.000#
*F and P values of major effect; # F and P values of interaction effects; Δ: F-test based on heterogeneity of variance. Note: OD value is propotinal to the number
of live cells and indirectly reflects cell proliferation.
 
Figure 4 Growth curves of nasopharyngeal carcinoma 5-8 F
cells transfected with pEGFP-C3-PinX1, pEGFP-C3, PinX1-FAM-
siRNA and treated with lipofectamine alone, indicating that
PinX1 overexpression significantly inhibited NPC 5-8 F cell
growth.
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merase activity in NPC 5-8 F cells (p =0 . 0 0 0 ) .B yc o n -
trast, reduced PinX1 by transfection of PinX1-FAM-
siRNA had effects on neither hTERT mRNA level nor
telomerase activity in NPC 5-8 F cells (p > 0.05). In
addition, hTERT mRNA level and telomerase activity in
NPC 5-8 F cells were not affected by transfection of
pEGFP-C3 and treatment of lipofectamine alone.
We next examined the effect of PinX1 on cell cycle by
flow cytometry. As shown in Table 6, overexpression of
PinX1 by transfection of pEGFP-C3-PinX1 significantly
increased the percentage of NPC 5-8 F cells at G0/G1
phase from 43.0% to 64.0% (p < 0.001). However, down-
regulation of Pin X1 by transfection of PinX1-FAM-
siRNA, liopafectamine treatment, and transfection of
pEGFP-C3 did not affect the percentage of NC 5-8 F
cells at G0/G1 phase.
We last examined the effect of PinX1 on NPC 5-8 F
apoptosis by Annexin V/PI staining. Living cells were
A n n e x i nV ( - ) / P I ( - )a tt h el o w e rl e f tq u a d r a n ti nf l o w
cytometry diagram. Cells with Annexin V(+)/PI(-) at the
lower right quadrant were at the early apoptotic status;
cells with Annexin V(-)/PI(+) at the upper right quad-
rant were at late apoptotic status. As shown in Table 7
and Figure 9, overexpression of PinX1 by transfection of
pEGFP-C3-PinX1 significantly enhanced AI from 19.266
± 0.763% in untreated cells and 19.566 ± 0.577% in
pEGFP-C3 transfected cells to 49.73 ± 2.ddxzr70% (p <
0.01). In addition, there was no difference of AI among
untreated cells, cells transfected with pEGFP-C3 and
cells treated with lipofectamine (p > 0.05).
Discussions
Telomerase is a special reverse transcriptase that is
composed of RNA and protein and regulates the length
of telomere. hTERT is the key component in telomerase
and plays important role in genetic stability and main-
tainance of chromosomes. Studies have found that telo-
merase is almost not expressed in normal somatic cells,
but its expression and activity are enhanced in most
immortalized tumor cells [18,19]. Previous studies from
our group and others have suggested that telomerase is
closely related to the incidence of vast majority of
human malignant tumors including nasopharyngeal car-
cinoma. Enhancement of its activity is the power source
of constantly increased proliferation, invasion and
metastasis of tumor cells. Therefore, downregulation of
telomerase activity in tumor cells is one of the impor-
tant therapeutic measures to inhibit tumor growth and
has become a hot topic in tumor gene therapy. Our
study and others have suggested that the targeted TK
gene therapy under hTERT promoter or enhanced
hTERT/CMV promoter can reduce telomerase activity,
eventually leading to the death of tumor cells including
NPC [6,7]. Thus, further exploration of specific telomer-
ase inhibitors will be a new direction for future research.
LPTS/PinX1 is recently discovered in cell nucleus as a
telomerase inhibitor that binds to Pin2/TRF1 complex
in vivo. PinX1 gene is located on chromosome 8p22-23
region, which has high frequency of loss of heterozygos-
ity (LOH) in a series of human cancer cells. LPTS is a
novel liver-related putative tumor suppressor gene. The
coding sequence of PinX1 is highly homologous to one
of the LPTS transcripts, LPTS-L, and considered as a
t r a n s c r i p to ft h es a m eg e n e[ 2 0 , 2 1 ] .S o m es t u d i e sh a v e
found that PinX1 can attenuate telomerase activity, inhi-
bit growth of tumor cells and induce apoptosis. Lack of
endogenous PinX1 leads to increased telomerase activity
and tumorigenicity in nude mice. Therefore, PinX1 is
considered as telomerase inhibitor and tumor suppres-
sor. Recent studies have also suggested that PinX1 as
tubulin plays an important role in the maintenance of
cell mitosis.
The mechanism of PinX1 functioning in tumor cells
has not been fully elucidated. Some studies indicate that
PinX1 gene can inhibit telomerase activity and induce
cell apoptosis, and expression of PinX1 is negatively cor-
related with hTERT expression and telomerase activity
in tumor cells. For examples, Liao et al. [10] reported
that upregulation of LPTS-L by transfection of its
expression vector in hepatoma cells can inhibit telomer-
ase activity and induce apoptosis; Zhang et al. [22]
reported that silencing PinX1 gene using short hairpin
RNA can lead to significant shortening of telomere and
growth inhibition of telomerase-positive tumor cell, but
not telomerase-negative tumor cells, indicating PinX1
affects telomere length and tumorigenicity through reg-
ulating telomerase activity; Cai et al. [23] found that
reduced PinX1 expression is highly correlated to the
poor prognostic factors (such as lymph node metastasis
and distant metastasis) in patients with ovarian cancer
and considered as an independent factor for poor prog-
nosis of patients with epithelial ovarian cancer; Wang et
al. [24] constructed and transfected PinX1 and PinX1-
siRNA eukaryotic expression vectors into gastric cancer
cells and found that downregulation of PinX1 by
Table 3 Chemotaxic activity of NPC cells in each group
(¯ X ± s)
Sample Chemotaxic activity (cell
number)
F P
pEGFP-C3-PinX1 17.75 ± 5.07*
pEGFP-C3 30.05 ± 7.22
Lipofectamine
alone
33.90 ± 7.92 17.162 0.000
Untreated 33.20 ± 8.61
PinX1-FAM-siRNA 33.50 ± 7.60**
*vs untreated, P < 0.001; ** vs untreated, P > 0.05.
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enhanced telomerase activity compared with that of
cells transfected with PinX1 vector, suggesting that
PinX1 is a telomerase inhibitor and inhibits tumorigen-
esis and development possibly through telomerase/
telomere pathway; Zhou et al.[ 2 5 ]b e l i e v e dt h a tP i n X 1
inhibits telomerase activity by binding to hTERT
through its TID domain, which consequently results in
telomere shortening, cell senescence and increase of
tumorigenicity in nude mice; Banik et al. [26] analyzed
     
   
Figure 5 Effect of PinX1 on nasopharyngeal carcinoma cell migration. Data were presented as mean number of cells migrated onto the
lower surface of transwell counted in five randomly selected fields under microscope. a: NPC 5-8 F cells transfected with pEGFP-C3-PinX1; b:
NPC 5-8 F cells transfected with pEGFP-C3; c: NPC 5-8 F cells treated with lipofectamine alone; d: untreated NPC 5-8 F cells; e: NPC 5-8 F cells
transfected with PinX1-FAM-siRNA.
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found that PinX1 can directly bind to hTERT and hTR,
but the binding of PinX1 to hTR is dependent on the
presence of hTERT. Inhibition of telomerase activity by
PinX1 requires its binding to both hTERT and hTR. By
contrast, some studies indicate that PinX1 expression is
positively correlated to telomerase activity. For exam-
ples, Sun et al. [12] found that PinX1 mRNA level is
     pEGFP-C3-PinX1 
     untreated 
   PinX1-FAM-siRNA 
       0 h                    1 2 h                  2 4 h               3 6 h  
Figure 6 Effect of PinX1 on wound healing ability of nasopharyngeal carcinoma 5-8 F cells in scratch assay. Cells transfected with
pEGFP-C3-PinX1 (a), pEGFP-C3 (b) and PinX1-FAM-siRNA(e), treated with lipofactamine alone (c), and untreated (d) were inoculated in 6-well
plates pre-coated with collagen IV, cultured in media containing 10% newborn calf serum till forming monolayer, then scratched and
photographed at 0 h, 12 h, 24 h and 36 h after scratching. The results show that overexpression of PinX1 by transfection of pEGFP-C3-PinX1
significantly increased the wound healing time of NPC 5-8 F cells, while downregulation of PinX1 by transfection of FAM-siRNA reduced has no
effect on wound healing.
Table 4 hTERT mRNA level in each group (¯ X ± s)
Sample hTERT mRNA F P
pEGFP-C3-PinX1 0.789 ± 0.024* 117.689 0.000
pEGFP-C3 0.978 ± 0.011
Lipofectamine alone 0.987 ± 0.014
Untreated 1.000 ± 0.000
PinX1-FAM-siRNA 1.001 ± 0.085**
* vs untreated, P < 0.001, ** vs untreated, P > 0.05. hTERT mRNA level was
normalized to GAPDH.
Table 5 Telomerase activity in NPC cells (¯ X ± s)
Samples Telomerase activity F P
pEGFP-C3-PinX1 36227.63 ± 2181.748* 53.816 0.000
pEGFP-C3 58346.993 ± 2181.748
Lipofectamine alone 59697.199 ± 2181.748
Untreated 62552.354 ± 2181.748
PinX1-FAM-siRNA 63600.608 ± 2181.748**
* vs untreated, P < 0.001; ** vs untreated, P > 0.05.
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acute promyelocytic leukemia cells and altered PinX1
expression is secondary response to changes of hTERT
expression. In addition, some studies found that PinX1
is not the key factor in inhibition of telomerase activity
and its function is rather related to gene polymorphism
than to telomerase activity. For example, studies [14] on
159 cases of hereditary prostate cancer identified 39
polymorphisms during PinX1 sequencing; studies [15]
on gastrointestinal cancer also found a missense
mutation (AGC/TGC) out of 254 codons in 1 case of
colon cancer and 1 case of esophageal cancer. The
authors suggested that this mutation may be a benign
polymorphism because neither de-hypermethylation on
its promoter region nor 5-N-2-deoxycytidine treatment
of a cell line affected PinX1 expression. In addition,
Chang et al. [16] analyzed the function of PinX1 in
medulloblastoma and found that 11 polymorphisms in
its 7 exons and their splicing sites by direct sequencing
and that telomerase activity was not inhibited and
related to PinX1, indicating PinX1 did not play a key
role in the process of medulloblastoma. Overall, the
mechanisms of PinX1 on telomerase/telomere are com-
plicated and may differ in different tumors. Recently,
researches on PinX1 dynamics and function have also
Figure 7 Effects of PinX1 on hTERT mRNA level in NPC 5-8 F
cells. PinX1 mRNA levels in NPC 5-8 F cells transfected with (a)
pEGFP-C3-PinX1, (b) with pEGFP-C3, (c) treated with lipofectamine
alone, (d) untreated and (e) transfected with PinX1-FAM-siRNA were
measured in RT-PCR and normalized to internal control GAPDH.
Data were presented as mean value of three experiments showing
that overexpression of PinX1 significantly decreased hTERT mRNA
level.
Figure 8 Effect of PinX1 on telomerase activity in nasopharyngeal carcinoma cells. Telomerase activity was measured by scratch assay in
NPC 5-8 F cells (a) transfected with PinX1-FAM-siRNA, (b) untreated, (c) treated with lipofectamine alone, (d) transfected with pEGFP-C3, (e)
transfected with pEGFP-C3-PinX1, and (f) human umbilical vein cells VEC-304. Lane (g) shows the DNA marker. The results indicate that
telomerase activity is weak in ECV-304 and strong in untreated NPC 5-8 F cells and overexpression of PinX1 by transfection of pEGFP-C3-PinX1
significantly inhibited telomerase activity in NPC cells, but not affected by transfection of PinX1-FAM-siRNA and pEGFP-C3, and treatment with
lipofectamine.
Table 6 Percentage of NPC cells in G0/G1 period (¯ X ± s)
Samples NPC in G0/G1 period (%) F P
pEGFP-C3-PinX1 64.000 ± 3.905* 50.006 0.000
pEGFP-C3 43.900 ± 2.193
Lipofectamine alone 42.966 ± 1.069
Untreated 43.033 ± 1625
PinX1-FAM-siRNA 42.833 ± 1.484**
* vs untreated, P < 0.001; ** vs untreated, P > 0.05.
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that PinX1 is located in the nucleolus and telomeres in
the interphase and gathered around chromosome and
outer plate of kinetochore in mitosis phase. Moreover,
downregulation of PinX1 by siRNA leads to the aberrant
separation of mitotic chromosome, suggesting that
PinX1 play an important role in mitotic chromosome
separation. Li et al. [27] further found that PinX1 is
recruited to the area surrounding chromosome by
nucleolin during mitosis to promote chromosomes con-
gression. Chen et al. [28] found that PinX1 binds to
Pin2/TRF1 and hTERT at different sites: LPTS/PinX1
(254- 289) binds to Pin2/TRF1, while LPTS/PinX1 (290-
328) binds to hTERT. Binding of LPTS/PinX1 (290-328)
to hTERT in vitro significantly inhibits telomerase activ-
ity, leading to telomere shortening and cell apoptosis.
In this study, we successfully constructed PinX1
expression vector pEGFP-C3-PinX1 and found its
transfection into NPC cells significantly increased
PinX1 mRNA level using RT-PCR, which laid the
foundation for study on the roles of PinX1 in NPC
cells. Our results also found that overexpression of
PinX1 by transfection of pEGFP-C3-PinX1 into NPC
cells significantly reduced hTERT mRNA level, telo-
merase activity, NPC cell growth, migration and
wound healing ability, arressted NPC cells in G0/G1
phase and induced cell apoptosis, whereas those phe-
nomena were not found in cells transfected with con-
trol vector pEGFP-C3 or treated with lipofectamine
alone compared with nontreated NPC cells. These sug-
gest that PinX1 is a potential inhibitor of telomerase
activity, in consistence with many other previous
reports on tumors.
To better understand the role of PinX1 on tumor
cells, we also successfully established PinX1-specific
siRNA PinX1-FAM-siRNA, transfection of which signifi-
cantly silenced 70% of endogenous PinX1 mRNA in
NPC cells (p < 0.001). However, PinX1 silencing did not
alter telomerase activity, and NPC cell growth and
migration. This discrepancy to previous studies [22,24]
m a yb ei n t e r p r e t e db yt h ef o l l o w i n g s :1 )e n d o g e n o u s
PinX1 level is already very low in tumor cells, therefore
further downregulation has little effect on telomerase
activity; 2) silencing PinX1 by transfection of PinX1-
FAM-siRNA may be not long enough to observe sub-
stantial biological alterations of tumor cells. But no mat-
ter how, PinX1-FAM-siRNA can inhibit PinX1
expression in vitro. Although few studies have been con-
ducted on PinX1 silencing, studies by Zhang et al. [22]
and Wang et al. [24] confirmed PinX1 is closely related
with telomerase activity.
Conclusions
In conclusion, this study systematically analyzed the
roles of PinX1 in NPC 5-8 F cells by oeverexpression or
downregulation of PinX1 and found that PinX1 affects
NPC cell growth, migration, wound healing ability and
cell cycles by inhibiting telomerase activity, suggesting
that PinX1 is a potential telomerase inhibitor and has
potential therapeutic application in treatment of tumors
including NPC. However, the study has some limita-
tions: 1) PinX1 and it siRNA are only transiently trans-
fected, their long-term effects on cells could not be
observed; 2) the in vitro experiments may not reflect its
role in vivo, therefore further evaluation of the experi-
mental results is needed.
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Table 7 Apoptotic index of NPC cells (¯ X ± s)
Samples Apoptotic index F P
pEGFP-C3-PinX1 49.733 ± 2.702* 183.419 0.000
pEGFP-C3 19.566 ± 0.577
Lipofectamine alone 19.066 ± 0.665
Untreated 19.266 ± 0.763
PinX1-FAM-siRNA 17.166 ± 2.663**
* vs untreated, P < 0.001; ** vs untreated, P > 0.05.
Apoptotic Index = apoptotic cell number/total cell number × 100%.
     
Figure 9 Effect of PinX1 on nasopharyngeal carcinoma cell
apoptosis measured by flow cytometry. Shown are the diagram
of flow cytometry of NPC 5-8 F cells stained with Annexin V and
propidium iodide solution (PI) and (a) transfected with pEGFP-C3-
PinX1, (b) transfected with pEGFP-C3, (c) treated with lipofectamine
alone, (d) untreated and (e) t transfected with PinX1-FAM-siRNA,
respectively. The upper and lower right quadrants represent
apoptotic cells and the lower left quadrant represents normal cells.
The data indicate that the number of apoptotic cells transfected
with pEGFP-C3-PinX1 was significantly greater than that of cells
treated otherwise.
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